特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
961213

オルニチントランスカルバミラーゼ欠損症の世界市場:タイプ別、アプリケーション別および地域別の市場規模と予測(2020年~2027年)

Global Ornithine-Transcarbamylase Deficiency Market Size study, by Type (DTX-301, SEL-313, SHP-641, PRX-OTC and Others), By Application (Hospital, Clinic and Others) and Regional Forecasts 2020-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
オルニチントランスカルバミラーゼ欠損症の世界市場:タイプ別、アプリケーション別および地域別の市場規模と予測(2020年~2027年)
出版日: 2020年09月15日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オルニチントランスカルバミラーゼ欠損症は、酵素オルニチントランスカルバミラーゼ(OTC)の完全な、または部分的な欠如によって特定される、高アンモニア血症を来す遺伝性疾患です。 OTC酵素の欠如は、高アンモニア血症という形で、窒素の過剰蓄積をもたらします。欠損症は窒素除去剤で治療することができます。また、主要企業は、激しい競合の中で自らを維持するために、製品の発売、革新、合併・買収などの戦略に焦点を合わせています。肥満の発生率の増加、過食症の増加、ジャンクフードの消費、および定期的な運動の欠如は、2020年から2027年の予測期間中の市場成長を促進する主要な要因となっています。経済協力開発機構(OCED)による肥満に関する最新情報(2017年版)によると、肥満レベルは徐々に増加すると予想され、米国、英国、メキシコなどの国々は肥満人口の主要なシェアを占める見込みです。 2030年までに米国の全人口の47%、メキシコの39%、英国の35%が肥満になると予測されています。また、OECDによると、2017年では英国は西欧で最大の肥満大国となり、さらに、Health at a Glance Reportによると、2015年の英国の人口の約26.9%が肥満であることが明らかになっています。また、OECDの報告書によると、英国の肥満は1990年代以来92%増加しています。

当レポートでは、世界のオルニチントランスカルバミラーゼ欠損症市場を調査し、全体的な市場動向、セグメント別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場の定義と範囲

第3章 市場力学

  • 市場影響分析(2018年~2027年)

第4章 市場の業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの提言と結論

第5章 タイプ別市場

  • 市場のスナップショット
  • タイプ別市場の実績-潜在力分析
  • タイプ別市場推定・予測、2017年~2027年(10億米ドル)
  • サブセグメント分析
    • DTX-301
    • SEL-313
    • SHP-641
    • PRX-OTC
    • その他

第6章 アプリケーション別市場

  • 市場のスナップショット
  • アプリケーション別市場の実績-潜在力分析
  • アプリケーション別市場推定・予測、2017年~2027年(10億米ドル)
  • サブセグメント分析
    • 病院
    • 診療所
    • その他

第7章 地域別分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第8章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Ultragenyx Pharmaceutical
    • Ucyclyd Pharma
    • Horizon Therapeutics plc
    • OrphanPacific, Inc.
    • Altis Endurance LLC
    • SEQENS GROUP
    • Bausch Health Companies, Inc.
    • Unicyte AG
    • Lucane Pharma SA
    • Promethera Biosciences SA

第9章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Ornithine-Transcarbamylase Deficiency market, report scope
  • TABLE 2. Global Ornithine-Transcarbamylase Deficiency market estimates & forecasts by region 2017-2027 (USD Billion)
  • TABLE 3. Global Ornithine-Transcarbamylase Deficiency market estimates & forecasts by Type 2017-2027 (USD Billion)
  • TABLE 4. Global Ornithine-Transcarbamylase Deficiency market estimates & forecasts by Application 017-2027 (USD Billion)
  • TABLE 5. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 6. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 7. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 8. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 9. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 10. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 11. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 12. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 13. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 14. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 15. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 16. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 17. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 18. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 19. Global Ornithine-Transcarbamylase Deficiency market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 20. Global Ornithine-Transcarbamylase Deficiency market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 21. U.S. Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 22. U.S. Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 23. U.S. Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 24. U.S. Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 25. Canada Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 26. Canada Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 27. Canada Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 28. Canada Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 29. UK Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 30. UK Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 31. UK Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 32. UK Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 33. Germany Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 34. Germany Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 35. Germany Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 36. Germany Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 37. France Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 38. France Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 39. France Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 40. France Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 41. Spain Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 42. Spain Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 43. Spain Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 44. Spain Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 45. Italy Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 46. Italy Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 47. Italy Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 48. Italy Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 49. ROE Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 50. ROE Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 51. ROE Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 52. ROE Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 53. China Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 54. China Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 55. China Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 56. China Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 57. India Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 58. India Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 59. India Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 60. India Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 61. Japan Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 62. Japan Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 63. Japan Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 64. Japan Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 65. Australia Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 66. Australia Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 67. Australia Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 68. Australia Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 69. South Korea Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 70. South Korea Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 71. South Korea Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 72. South Korea Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 73. ROPAC Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 74. ROPAC Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 75. ROPAC Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 76. ROPAC Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 77. Brazil Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 78. Brazil Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 79. Brazil Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 80. Brazil Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 81. Mexico Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 82. Mexico Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 83. Mexico Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 84. Mexico Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 85. ROLA Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 86. ROLA Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 87. ROLA Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 88. ROLA Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 89. ROW Ornithine-Transcarbamylase Deficiency market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 90. ROW Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 91. ROW Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 92. ROW Ornithine-Transcarbamylase Deficiency market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 93. List of secondary sources, used in the study of global Ornithine-Transcarbamylase Deficiency market
  • TABLE 94. List of primary sources, used in the study of global Ornithine-Transcarbamylase Deficiency market
  • TABLE 95. Years considered for the study
  • TABLE 96. Exchange rates considered

LIST OF FIGURES

  • FIG 1. Global Ornithine-Transcarbamylase Deficiency market, research methodology
  • FIG 2. Global Ornithine-Transcarbamylase Deficiency market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Ornithine-Transcarbamylase Deficiency market, key trends 2019
  • FIG 5. Global Ornithine-Transcarbamylase Deficiency market, growth prospects 2020-2027
  • FIG 6. Global Ornithine-Transcarbamylase Deficiency market, porters 5 force model
  • FIG 7. Global Ornithine-Transcarbamylase Deficiency market, pest analysis
  • FIG 8. Global Ornithine-Transcarbamylase Deficiency market, value chain analysis
  • FIG 9. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 10. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 11. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 12. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 13. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 14. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 15. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 16. Global Ornithine-Transcarbamylase Deficiency market by segment, 2017 & 2027 (USD Billion)
  • FIG 17. Global Ornithine-Transcarbamylase Deficiency market, regional snapshot 2017 & 2027
  • FIG 18. North America Ornithine-Transcarbamylase Deficiency market 2017 & 2027 (USD Billion)
  • FIG 19. Europe Ornithine-Transcarbamylase Deficiency market 2017 & 2027 (USD Billion)
  • FIG 20. Asia Pacific Ornithine-Transcarbamylase Deficiency market 2017 & 2027 (USD Billion)
  • FIG 21. Latin America Ornithine-Transcarbamylase Deficiency market 2017 & 2027 (USD Billion)
  • FIG 22. Global Ornithine-Transcarbamylase Deficiency market, company market share analysis (2019)
目次

Global Ornithine-Transcarbamylase Deficiency Market is valued approximately USD XXX million in 2019 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2020-2027. Ornithine-Transcarbamylase Deficiency is an inherited disorder that causes ammonia in the blood which is identified by complete or partial lack of enzyme ornithine trascarbamylase (OTC). The lack of OTC enzyme concludes in excessive accumulation of nitrogen, in form of ammonia in the blood. The deficiency can be treated by nitrogen scavenging agents. Also, the key players are focusing on strategies such as product launch, innovation and merger & acquisition to sustain themselves amidst fierce competition. Rising incidences of obesity, rising binge eating and consumption of junk foods along with the neglect towards regular exercising are some major drivers supplementing the growth of the market during the forecast period of 2020-2027. According to Obesity Update 2017 by Organization for Economic Co-operation and Development (OCED), the obesity levels are anticipated to increase gradually and countries such as United States, England and Mexico would be having major shares of their population suffering with obesity. U.S. with 47%, 39% of total population in Mexico and 35% population of England is projected to be obese by 2030. Also, according to the Organization for Economic Co-operation and Development in 2017, United Kingdom is the most obese country in Western Europe. Additionally, as per the Health at a Glance Report, reveals that approximately 26.9 % of the UK population is obese in 2015. Also, as per the Organization for Economic Co-operation and Development (OECD) report, obesity in United Kingdom has increased by 92% since the 1990's.

The regional analysis of global Ornithine-Transcarbamylase Deficiency market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region due to the availability of well-defined reimbursement policies from private and public health insurance firms, which help provide the extensive research & development activities and easy access to diagnosis. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:

Ultragenyx Pharmaceutical

Ucyclyd Pharma

Horizon Therapeutics plc

OrphanPacific, Inc.

Altis Endurance LLC

Seqens Group

Bausch Health Companies, Inc.

Unicyte AG

Lucane Pharma SA

Promethera Biosciences SA

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

DTX-301

SEL-313

SHP-641

PRX-OTC

Others

By Application:

Hospital

Clinic

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Ornithine-Transcarbamylase Deficiency Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Ornithine-Transcarbamylase Deficiency Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Ornithine-Transcarbamylase Deficiency Market, by Type 2018-2027 (USD Billion)
    • 1.2.3. Ornithine-Transcarbamylase Deficiency Market, by Applications 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Ornithine-Transcarbamylase Deficiency Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Ornithine-Transcarbamylase Deficiency Market Dynamics

  • 3.1. Ornithine-Transcarbamylase Deficiency Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Ornithine-Transcarbamylase Deficiency Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Ornithine-Transcarbamylase Deficiency Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Ornithine-Transcarbamylase Deficiency Market by Type, Performance - Potential Analysis
  • 5.3. Global Ornithine-Transcarbamylase Deficiency Market Estimates & Forecasts by Type 2017-2027 (USD Billion)
  • 5.4. Ornithine-Transcarbamylase Deficiency Market, Sub Segment Analysis
    • 5.4.1. DTX-301
    • 5.4.2. SEL-313
    • 5.4.3. SHP-641
    • 5.4.4. PRX-OTC
    • 5.4.5. Others

Chapter 6. Global Ornithine-Transcarbamylase Deficiency Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Ornithine-Transcarbamylase Deficiency Market by Application, Performance - Potential Analysis
  • 6.3. Global Ornithine-Transcarbamylase Deficiency Market Estimates & Forecasts by Application 2017 -2027 (USD Billion)
  • 6.4. Ornithine-Transcarbamylase Deficiency Market, Sub Segment Analysis
    • 6.4.1. Hospital
    • 6.4.2. Clinic
    • 6.4.3. Others

Chapter 7. Global Ornithine-Transcarbamylase Deficiency Market, Regional Analysis

  • 7.1. Ornithine-Transcarbamylase Deficiency Market, Regional Market Snapshot
  • 7.2. North America Ornithine-Transcarbamylase Deficiency Market
    • 7.2.1. U.S. Ornithine-Transcarbamylase Deficiency Market
      • 7.2.1.1. Type breakdown estimates & forecasts, 2017-2027
      • 7.2.1.2. Application breakdown estimates & forecasts, 2017-2027
    • 7.2.2. Canada Ornithine-Transcarbamylase Deficiency Market
  • 7.3. Europe Ornithine-Transcarbamylase Deficiency Market Snapshot
    • 7.3.1. U.K. Ornithine-Transcarbamylase Deficiency Market
    • 7.3.2. Germany Ornithine-Transcarbamylase Deficiency Market
    • 7.3.3. France Ornithine-Transcarbamylase Deficiency Market
    • 7.3.4. Spain Ornithine-Transcarbamylase Deficiency Market
    • 7.3.5. Italy Ornithine-Transcarbamylase Deficiency Market
    • 7.3.6. Rest of Europe Ornithine-Transcarbamylase Deficiency Market
  • 7.4. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Snapshot
    • 7.4.1. China Ornithine-Transcarbamylase Deficiency Market
    • 7.4.2. India Ornithine-Transcarbamylase Deficiency Market
    • 7.4.3. Japan Ornithine-Transcarbamylase Deficiency Market
    • 7.4.4. Australia Ornithine-Transcarbamylase Deficiency Market
    • 7.4.5. South Korea Ornithine-Transcarbamylase Deficiency Market
    • 7.4.6. Rest of Asia Pacific Ornithine-Transcarbamylase Deficiency Market
  • 7.5. Latin America Ornithine-Transcarbamylase Deficiency Market Snapshot
    • 7.5.1. Brazil Ornithine-Transcarbamylase Deficiency Market
    • 7.5.2. Mexico Ornithine-Transcarbamylase Deficiency Market
  • 7.6. Rest of The World Ornithine-Transcarbamylase Deficiency Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. Ultragenyx Pharmaceutical
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Ucyclyd Pharma
    • 8.2.3. Horizon Therapeutics plc
    • 8.2.4. OrphanPacific, Inc.
    • 8.2.5. Altis Endurance LLC
    • 8.2.6. SEQENS GROUP
    • 8.2.7. Bausch Health Companies, Inc.
    • 8.2.8. Unicyte AG
    • 8.2.9. Lucane Pharma SA
    • 8.2.10. Promethera Biosciences SA

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.